C5a and bradykinin receptor cross-talk regulates innate and adaptive immunity in trypanosoma cruzi infection

Journal of Immunology

Volumn 193, Issue 7, 2014, Pages 3613-3623

  Schmitz, Veronica ^a,b   Almeida, Larissa Nogueira ^a   Svensjö, Erik ^a   Monteiro, Ana Carolina ^a   Köhl, Jörg ^c,d   Scharfstein, Julio ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF LÜBECK   (Germany)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B2 RECEPTOR; BRADYKININ RECEPTOR; CAPTOPRIL; COMPLEMENT COMPONENT C5A RECEPTOR; CRUZIPAIN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; ICATIBANT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; C5AR1 PROTEIN, MOUSE; COMPLEMENT COMPONENT C5A; CYSTEINE PROTEINASE; CYTOKINE; PARASITE ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELL MIGRATION; CELLULAR IMMUNITY; CHAGAS DISEASE; CHEEK POUCH; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DOSE RESPONSE; DRUG TARGETING; EFFECTOR CELL; HAMSTER; IMMUNOREGULATION; INFECTION SENSITIVITY; INNATE IMMUNITY; INTERFERON PRODUCTION; LYMPHOCYTE DIFFERENTIATION; MALE; MOLECULAR INTERACTION; NONHUMAN; PAW EDEMA; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SINGLE DRUG DOSE; TH1 CELL; TRYPOMASTIGOTE; ANIMAL; BAGG ALBINO MOUSE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MOUSE; PATHOLOGY; TRYPANOSOMA CRUZI;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, PROTOZOAN; CHAGAS DISEASE; COMPLEMENT C5A; CRICETINAE; CYSTEINE ENDOPEPTIDASES; CYTOKINES; IMMUNITY, INNATE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTOR, BRADYKININ B2; TH1 CELLS; TRYPANOSOMA CRUZI;

EID: 84907202536     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302417     Document Type: Article

References (80)

1. Lambris, J. D., D. Ricklin, and B. V. Geisbrecht. 2008. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6: 132-142.
2. Klos, A., A. J. Tenner, K. O. Johswich, R. R. Ager, E. S. Reis, and J. Köhl. 2009. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46: 2753-2766.
3. Ger ard, N. P., and C. Gerard. 1991. The chemotactic receptor for human C5a anaphylatoxin. Nature 349: 614-617.
4. Gerard, C., and N. P. Gerard. 1994. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu. Rev. Immunol. 12: 775-808.
5. Li, R., L. G. Coulthard, M. C. Wu, S. M. Taylor, and T. M. Woodruff. 2013. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J. 27: 855-864.
6. Wetsel, R. A. 1995. Expression of the complement C5a anaphylatoxin receptor (C5aR) on non-myeloid cells. Immunol. Lett. 44: 183-187.
7. Lalli, P. N., M. G. Strainic, M. Yang, F. Lin, M. E. Medof, and P. S. Heeger. 2008. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-c ell expansion by limiting antigen-induced apoptosis. Blood 112: 1759-1766.
8. Peng, Q., K. Li, K. Anderson, C. A. Farrar, B. Lu, R. A. Smith, S. H. Sacks, and W. Zhou. 2008. Local prod uction and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction. Blood 111: 2452-2461.
9. Peng, Q., K. Li, N. Wang, Q. Li, E. Asgari, B. Lu, T. M. Woodruff, S. H. Sacks, and W. Zhou. 2009. Dendritic cell function in allostimulation is modulated by C5aR signaling. J. Immunol. 183: 6058-6068.
10. Li, K., K. J. Anderson, Q . Peng, A. Noble, B. Lu, A. P. Kelly, N. Wang, S. H. Sacks, and W. Zhou. 2008. Cyclic AMP plays a critical role in C3areceptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation. Blood 112: 5084-5094.
11. Strainic, M. G., J. Liu, D. Huang, F. An, P. N. Lalli, N. Muqim, V. S. Shapiro, G. R. Dubyak, P. S. Heeger, and M. E. Medof. 2008. Locally produced complem ent fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28: 425-435.
12. Weaver, D. J., Jr., E. S. Reis, M. K. Pandey, G. Kö hl, N. Harris, C. Gerard, and J. Kö hl. 2010. C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. Eur. J. Immunol. 40: 710-721.
13. Sacks S.H., 2010. Complement fragments C3a and C5a: the salt and pepper of the immune response. Eur. J. Immunol., 40, 668-670.
14. Strainic, M. G., E. M. Shevach, F. An, F. Lin, and M. E. Medof. 2013. Absence of signaling into CD4+ cells via C3aR and C5aR enables autoinductive TGF-b1 signaling and induction of Foxp3+ regulatory T cells. Nat. Immunol. 14: 162-171.
15. Kwan, W. H., W . van der Touw, E. Paz-Artal, M. O. Li, and P. S. Heeger. 2013. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. J. Exp. Med. 210: 257-268.
16. Coura, J. R., and J. C. Dias. 2009. Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Mem. Inst. Oswaldo Cruz 104 (Suppl 1): 31-40.
17. Kollien, A. H., and G. A. Schaub . 2000. The development of Trypanosoma cruzi in triatominae. Parasitol. Today (Regul. Ed.) 16: 381-387.
18. Cortez, C., N. Yoshida, D. Bahia, and T. J. Sobreira. 2012. Structural basis of the interaction of a Trypanosoma cruzi surface molecule implicated in oral infection with host cells and gastric mucin. PLoS ONE 7: e42153.
19. Krautz, G. M., J. C. Kissinger, and A. U. Krettli. 2000. The target s of the lytic antibody response against Trypanosoma cruzi. Parasitol. Today (Regul. Ed.) 16: 31-34.
20. Almeida, I. C., M. A. Ferguson, S. Schenkman, and L. R. Travassos. 1994. Lytic anti-alpha-galac tosyl antibodies from patients with chronic Chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi. Biochem. J. 304: 793-802.
21. Golgher, D., and R. T. Gazzinelli. 2004. Innate and acquired immunity in the pathogenesis of Chagas disease. Autoimmunity 37: 399-409.
22. Padilla, A. M., J. M. Bustamante, and R. L. Tarleto n. 2009. CD8+ T cells in Trypanosoma cruzi infection. Curr. Opin. Immunol. 21: 385-390.
23. Marin-Neto, J. A., E. Cunha-Neto, B. C. Maciel, and M. V. Simo?es. 2007. Pathogenesis of chronic Chagas heart disease. Circulation 115: 1109-1123.
24. Tarleton, R. L. 2001. Parasite persistence in the aetiology of Chagas disease. Int. J. Parasitol. 31: 550-554.
25. Souza, P. E., M. O. Rocha, E. Rocha-Vieira, C. A. Menezes, A. C. Chaves, K. J. Gollob, and W. O. Dutra. 2004. Monocytes from patients with indeterminate and cardiac forms of Chagas' disease display distinct phenotypic and functional characteristics associated with morbidity. Infect. Immun. 72: 5283-5291.
26. Villani, F. N. A., M. O. C. Rocha, Mdo. C. Nunes, L. R. V. Antonelli, L. M. D. Magalha?es, J. S. C. dos Santos, K. J. Gollo b, and W. O. Dutra. 2010. Trypanosoma cruzi-induced activation of functionally distinct ab and gd CD4-CD8-T cells in individuals with polar forms of Chagas' disease. Infect. Immun. 78: 4421-4430.
27. de Araújo, F. F ., R. Corrê a-Oliveira, M. O. Rocha, A. T. Chaves, J. A. Fiuza, R. C. Fares, K. S. Ferreira, M. C. Nunes, T. S. Keesen, M. P. Damasio, et al. 2012. Foxp3+CD25(high) CD4+ regulatory T cells from indetermina te patients with Chagas disease can suppress the effector cells and cytokines and reveal altered correlations with disease severity. Immunobiology 217: 768-777.
28. Guedes, P. M., F. R. Gutierrez, G. K. Silva, R. Dellalibera-Joviliano, G. J. Rodrigues, L. M. Bendhack, A. Rassi, Jr., A. Rassi, A. Schmidt, B. C. Maciel, et al. 2012. Deficient regulatory T cell activity and low frequency of IL-17 producing T cells correlate with the extent of cardiomyopathy in human Chagas' disease. PLoS Negl. Trop. Dis. 6: e1630.
29. Reis, D. D., E. M. Jones, S. Tostes, Jr., E. R. Lopes, G. Gazzinelli, D. G. Colley, and T. L. McCurley. 1993. Characterization of inflammatory infiltrates in chronic chagasic myocardial lesions: presence of tumor necrosis factor-alpha+ cells and dominance of granzyme A+, CD8+ lymphocytes. Am. J. Trop. Med. Hyg. 48: 637-644.
30. Silverio, J. C., I. R. Pereira, Mda. C. Cipitelli, N. F. Vinagre, M. M. Rodrigues, R. T. Gazzinelli, and J. Lannes-Vieira. 2012. CD8+ T-cells expressing interferon gamma or perforin play antagonistic roles in heart injury in experimental Trypanosoma cruzi-elicited cardiomyopathy. PLoS Pathog. 8: e100264 5.
31. Higuchi, Mde. L., L. A. Benvenuti, M. Martins Reis, and M. Metzger. 2003. Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovasc. Res. 60: 96-107.
32. Tanowitz, H. B., H. Huang, L. A. Jelicks, M. Chandra, M. L. Loredo, L. M. Weiss, S. M. Factor, V. Shtutin, S. Mukherjee, R. N. Kitsis, et al. 2005. Role of endothelin 1 in the pathogen esis of chronic chagasic heart disease. Infect. Immun. 73: 2496-2503.
33. Scharfstein, J., D. Andrade, E. Svensjö, A. C. Oliveira, and C. R. Nascimento. 2012. The kallikrein-kinin system in expe rimental Chagas disease: a paradigm to investigate the impact of inflammatory edema on GPCR-mediated pathways of host cell invasion by Trypanosoma cruzi. Front. Immunol. 3: 396.
34. Nery E. D.,M. A. Juliano,M. Meldal,I. Svendsen,J. Scharfstein,A. Walmsley,L. Juliano., 1997, Characterization of the substrate specificity of the major cysteine protease (cruzipain) from Trypanosoma cruzi using a portion-mixing combinatorial library an d fluorogenic peptides, Biochem. J., 323, 427-433.
35. Lima, A. P., P. C. Almeida, I. L. Tersariol, V. Schmitz, A. H. Schmaier, L. Juliano, I. Y. Hirata, W. Müller-Esterl, J. R. Chagas, and J. Scharfstein. 2002. Heparan sulfate modulates kinin release by Trypanosoma cruzi through the activity of cruzipain. J. Biol. Chem. 277: 5875-5881.
36. Scharfstein, J., V. Schmitz, V. Morandi, M. M. Capella, A. P. Lima, A. Morrot, L. Juliano, and W. Muller-Esterl. 2000. Host cell invasion by Trypanosoma cruzi is potentiated by activation of bradykinin B(2) receptors. J. Exp. Med. 192: 1289-1300.
37. Todorov, A. G., D. Andrade, J. B. Pesquero, Rde. C. Araujo, M. Bader, J. Stewart, L. Gera, W. Müller-Esterl, V. Morandi, R. C. Goldenberg, et al. 2003. Trypanosoma cruzi induces edem atogenic responses in mice and invades cardiomyocytes and endothelial cells in vitro by activating distinct kinin receptor (B1/B2) subtypes. FASEB J. 17: 73-75.
38. Monteiro, A. C., V. Schmitz, E. Svensjo, R. T. Gazzinelli, I. C. Almeida, A. Todorov, L. B. de Arruda, A. C. Torrecilhas, J. B. Pesquero, A. Morrot, et al. 2006. Cooperative activation of TLR2 and bradykinin B2 receptor is required for induction of type 1 i mmunity in a mouse model of subcutaneous infection by Trypanosoma cruzi. J. Immunol. 177: 6325-6335.
39. Barr, S. C., K. L. Warner, B. G. Kornreic, J. Piscitelli, A. Wolfe, L. Benet, and J. H. McKerrow. 2005. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob. Agents Chemother. 49: 5160-5161.
40. Andrade, D., R. Serra, E. Svensjö , A. P. Lima, E. S. Ramos, Jr., F. S. Fortes, A. C. Morandini, V. Morandi, Mde. N. Soeiro, H. B. Tanowitz, and J. Scharfstein. 2012. Trypanosoma cruzi invades host cells through the activation of endothelin and bradykini n receptors: a converging pathway leading to chagasic vasculopathy. Br. J. Pharmacol. 165: 1333-1347.
41. Aliberti, J., J. P. Viola, A. Vieira-de-Abreu, P. T. Bozza, A. Sher, and J. Scharfstein. 20 03. Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. J. Immunol. 170: 5349-5353.
42. Monteiro, A. C., V. Schmitz, A. Morrot, L. B. de Arruda, F. Nagajyothi, A. Granato, J. B. Pesquero, W. Müller-Esterl, H. B. Tanowitz, and J. Scharfstein. 2007. Bradykinin B2 Receptors of den dritic cells, acting as sensors of kinins proteolytically released by Trypanosoma cruzi, are critical for the development of protective type-1 responses. PLoS Pathog. 3: e185.
43. Rupniak, N. M., S. Boyce, J. K. Webb, A. R. Williams, E. J. Carlson, R. G. Hill, J. A. Borkowski, and J. F. Hess. 1997. Effects of the bradykinin B1 receptor antagonist des-Arg9[Leu8]bradykinin and genetic disruption of the B2 receptor on nociception in rats and mice. Pain 71: 89-97.
44. Klos, A., V. Ihrig, M. Messner, J. Grabbe, and D. Bitter-Suermann. 1988. Detection of native human complement components C3 and C5 and their primary activati on peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies. J. Immunol. Methods 111: 241-252.
45. Otto, M., H. Hawlisch, P. N. Monk, M. Müller, A. Klos, C. L. Karp, and J. Kö hl. 2004. C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. J. Biol. Chem. 279: 142-151.
46. Miranda, K. M., M. G. Espey, and D. A. Wink. 2001. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5: 62-71.
47. Ames, R. S., D. Lee, J. J. Foley, A . J. Jurewicz, M. A. Tornetta, W. Bautsch, B. Settmacher, A. Klos, K. F. Erhard, R. D. Cousins, et al. 2001. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antii nflammatory activity in animal models. J. Immunol. 166: 6341-6348.
48. Schmitz, V., E. Svensjö , R. R. Serra, M. M. Teixeira, and J. Scharfstein. 2009. Proteolytic generation of kinins in tiss ues infected by Trypanosoma cruzi depends on CXC chemokine secretion by macrophages activated via Toll-like 2 receptors. J. Leukoc. Biol. 85: 1005-1014.
49. Svensjö , E., E. M. Saraiva, R. S. Amendola, C. Barja-Fidalgo, M. T. Bozza, E. A. Lerner, M. M. Teixeira, and J. Scharfstein. 2012. Maxadilan, the Lutzomyia longipalpis vasodilator, drives plasma leakage via PAC1-CXCR1/2-pathway. Microvasc. Res. 83: 185-193.
50. Wetsel, R. A., D. T. Fleischer, and D. L. Haviland. 1990. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 59-exon. J. Biol. Chem. 265: 2435-2440.
51. Silva, J. S., D. R. Twardzik, and S. G. Reed. 1991. Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor b (TGF-b). J. Exp. Med. 174: 539-545.
52. Scharfstein, J., and D. Andrade. 2011. Infection-associated vasculopathy in experimental chagas disease pathogenic roles of endothelin and kinin pathways. Adv. Parasitol. 76: 101-127.
53. Valc k, C., G. Ramírez, N. López, C. H. Ribeiro, I. Maldonado, G. Sánchez, V. P. Ferreira, W. Schwaeble, and A. Ferreira. 2010. Molecular mechanisms involved in the inactivation of the first component of human complement by Trypanosoma cruzi calreticulin. Mol. Immunol. 47: 1516-1521.
54. Kö hl, J. 2006. The role of complement in danger sensing and transmission. Immunol. Res. 34: 157-176.
55. K emper, C., J. P. Atkinson, and D. E. Hourcade. 2010. Properdin: emerging roles of a pattern-recognition molecule. Annu. Rev. Immunol. 28: 131-155.
56. Buscaglia, C. A., V. A. Campo, A. C. Frasch, and J. M. Di Noia. 2006. Trypanosoma cruzi surface mucins: host-dependent coat diversity. Nat. Rev. Microbiol. 4: 229-236.
57. Huber-La ng, M., J. V. Sarma, F. S. Zetoune, D. Rittirsch, T. A. Neff, S. R. McGuire, J. D. Lambris, R. L. Warner, M. A. Flierl, L. M. Hoesel, et al. 2006. Generation of C5a in the absence of C3: a new complement ac tivation pathway. Nat. Med. 12: 682-687.
58. Amara, U., M. A. Flierl, D. Rittirsch, A. Klos, H. Chen, B. Acker, U. B. Brückner, B. Nilsson, F. Gebhard, J. D. Lambris, and M. Huber-L ang. 2010. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 185: 5628-5636.
59. Huber-Lang, M., E. M. Younkin, J. V. Sarma, N. Riedemann, S. R. McGuire, K. T. Lu, R. Kunkel, J. G. Younger, F. S. Zetoune, and P. A. Ward. 2002. Generation of C5a by phagocytic cells. Am. J. Pathol. 161: 1849-1859.
60. Perl, M., S. Denk, M. Kalbitz, and M. Hu ber-Lang. 2012. Granzyme B: a new crossroad of complement and apoptosis. Adv. Exp. Med. Biol. 946: 135-146.
61. Kemper, C., and J. Kö hl. 2013. Novel roles for complement receptors in T cell regulation and beyond. Mol. Immunol. 56: 181-190.
62. Maruo, K., T. Akaike, T. Ono, T. Okamoto, and H. Maeda. 1997. Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease. J. Allergy Clin. Immunol. 100: 253-260.
63. Wingrove, J. A., R. G. DiScipio, Z. Chen, J. Potempa, J. Travis, and T. E. Hugli. 1992. Activation of complement components C3 and C5 by a cys teine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis. J. Biol. Chem. 267: 18902-18907.
64. Discipio, R. G., P. J. Daffern, M. Kawahara, R. Pike, J. Travis, T. E. Hugli, and J. Potempa. 1996. Cleavage of human complement component C5 by cysteine proteinases from Porphyromonas (Bacteroides) gingivalis. Prior oxidation of C5 augments proteinase digestion of C5. Immunology 87: 660-667.
65. Nitta, H., T. Imamura, Y. Wada, A. Irie, H. Kobayashi, K. Okamoto, and H. Baba. 2008. Production of C5a by ASP, a serine protease released from Aeromonas sobria. J. Immunol. 181: 3602-3608.
66. Calixto, J. B., R. Medeiros, E. S. Fernandes, J. Ferreira, D. A. Cabrini, and M. M. Campos. 2004. Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br. J . Pharmacol. 143: 803-818.
67. Gutierrez, F. R., M. M. Lalu, F. S. Mariano, C. M. Milanezi, J. Cena, R. F. Gerlach, J. E. Santos, D. Torres-Duen?as, F. Q. Cunha, R. Schulz, and J. S . Silva. 2008. Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection. J. Infect. Dis. 197: 1468-1476.
68. Vespa, G. N., F. Q. Cunha, and J. S. Silva. 1994. Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect. Immun. 62: 5177-5182.
69. Doyle, P. S., Y. M. Zhou, I. Hsieh, D. C. Greenbaum, J. H. McKerrow, and J. C. Engel. 2011. The Trypanosoma cruzi protease cruzain mediates immune evasion. PLoS Pathog. 7: e1002139.
70. Venturini, G., L. Salvati, M. Muolo, M. Colasanti, L. Gradoni, and P. Ascenzi. 2000. Nitric oxide inhibits cruzipain, the major papain-like cysteine proteinase from Trypanosoma cruzi. Biochem. Biophys. Res. Commun. 270: 437-441.
71. Zhou, W. 2012. The new face of anaphylatoxins in immune regulation. Immunobiology 217: 225-234.
72. Hawlisch, H., Y. Belkaid, R. Baelder, D. Hildeman, C. Gerard, and J. Köhl. 2005. C5a negatively regulates toll-like recept or 4-induced immune responses. Immunity 22: 415-426.
73. Marshall, J. S. 2004. Mast-cell responses to pathogens. Nat. Rev. Immunol. 4: 787-799.
74. Wittmann, M., J. Zwi rner, V. A. Larsson, K. Kirchhoff, G. Begemann, A. Kapp, O. Götze, and T. Werfel. 1999. C5a suppresses the production of IL-12 by IFN-gamma-primed and lipopolysaccharide-challenged human monocytes. J. Immunol. 162: 6763-6769.
75. Braun, M. C., E. Lahey, and B. L. Kelsall. 2000. Selective suppression of IL-12 production by chemoattractants. J. Immunol. 164: 3009-3017.
76. Karp, C. L., A. Grupe, E. Schadt, S. L. Ewart, M. Keane-Moore, P. J. Cuomo, J. Kö hl, L. Wahl, D. Kuperman, S. Germer, et al. 2000. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat. Immunol. 1: 221-226.
77. Sansonetti P. J., 2006, The innate signaling of dangers and the dangers of innate signaling. Nat. Immunol., 7, 1237-1242.
78. Liu, J., F. Lin, M. G. Strainic, F. An, R. H. Miller, C. Z. Altuntas, P. S. Heeger, V. K. Tuohy, and M. E. Medof. 2008. IFN-g and IL-17 production in experimental autoimmune encephalomyelitis de pends on local APC-T cell complement production. J. Immunol. 180: 5882-5889.
79. Kö hl, J., R. Baelder, I. P. Lewkowich, M. K. Pandey, H. Hawlisch, L. Wang, J. Best, N. S. Herman, A. A. Spr oles, J. Zwirner, et al. 2006. A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J. Clin. Invest. 116: 783-796.
80. Köhl, J., and M. Wills-Karp. 2007. Complement regu lates inhalation tolerance at the dendritic cell/T cell interface. Mol. Immunol. 44: 44-56.